Engineered immune cells take on stomach cancer in early trial
NCT ID NCT07509008
First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times
Summary
This early-phase trial tests a new treatment for stomach cancer that has spread to the lining of the abdomen. Ten adults will receive specially engineered immune cells (NK cells) infused directly into the abdomen, along with standard chemotherapy drugs. The main goals are to find a safe dose and check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- engineered natural killer (NK) cells
- What this could lead to
- If it works, this could point toward a new treatment option for stomach cancer that has spread to the abdomen.
- What could go wrong
- This is a very early, small trial (10 people) focused on safety and dosing. The treatment may not work or could cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA METASTATIC TO THE PERITONEUM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UT MD Anderson
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.